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Neurotoxicology is a relatively young discipline that has undergone significant growth during the
last 25 years. During the late 1970s and 1980s, numerous national and international conferences
and meetings were devoted to the topic of neurotoxicology, the formation of societies or specialty
sections related to neurotoxicology, and the establishment of two independent peer-reviewed
journals devoted to neurotoxicology. This decade was also associated with a rapid increase in our
knowledge of chemical effects on the structure and function of the nervous system. During the
1990s, regulatory agencies such as the U.S. Environmental Protection Agency accepted
neurotoxicology as a crucial end point and neurotoxicity testing and risk assessment guidelines
were published. Neurotoxicology has also been accepted at the international level as evidenced by
environmental criteria documents published by the International Programme on Chemical Safety
and testing guidelines by the Organization of Economic Cooperation and Development. In recent
years, there has been increased concern that the etiology of some neurodegenerative diseases
may be associated with exposure to neurotoxic agents and that subpopulations of humans such as
children and the elderly may be differentially sensitive to neurotoxic exposure. In the future,
mechanistic information derived from basic research will be used in the identification and
characterization of chemicals with neurotoxic potential. Key words: future directions,
neurotoxicology, neurotoxicology risk assessment guidelines. - Environ Health Perspect
108(suppl 3):439-441 (2000).
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In 1980, Reiter (1) wrote that neurotoxicolo-
gists should move into the mainstream of
environmental toxicology by developing a
research strategy to evaluate the multitude of
chemicals and mixtures in the environment.
Ten years later, Tilson (2) documented the
general growth ofthe discipline ofneurotoxi-
cology as evidenced bythe number ofnational
and international conferences, formation of
scientific societies or specialty sections, estab-
lishment ofpeer-reviewed journals, and the
large increase in the number ofscientific
papers and books published on topics related
to neurotoxicology. In 1990, the Office of
Technology Assessment (3) published a book
reviewing the basic principles and status of
neurotoxicology research in the federal gov-
ernment. Acceptance ofneurotoxicology at
the international level was noted in a publica-
tion by the International Programme on
Chemical Safety/World Health Organization
(IPCS/WHO) of an environmental criteria
document (4) on the principles and methods
for assessment ofneurotoxicity associatedwith
exposure to chemicals.
Significant progress was made in three
areas during the 1980s to address the concern
raised by Reiter (1), i.e., the development ofa
research strategy to assess the large number of
chemicals in the environment. One impor-
tant development was the general acceptance
ofbehavioral procedures in neurotoxicologi-
cal studies. Prior to the 1980s, it was gener-
ally accepted that chemical-induced changes
in the structure of the nervous system were
adverse, whereas changes in behavior were
not universally accepted as evidence ofneuro-
toxicity. Determination ofthe sensitivity and
selectivity ofbehavioral changes became an
important issue, since it was argued that such
changes might precede neuropathological
changes and provide a more sensitive indica-
tor ofa chemical's neurotoxicity. Mello (5)
was among the first to argue that the behavior
oforganisms represents a functional integra-
tion ofthe nervous system and that nervous
system capacity cannot be assessed in neuro-
histological or physiological studies indepen-
dent ofbehavioral analyses. On this basis, it
was argued that behavioral measures have sig-
nificant potential in the study ofdeleterious
effects ofchemicals on the nervous system
(6). In the 1980s there was a large increase in
the number ofstudies using behavioral proce-
dures to investigate the effects ofchemicals
on the nervous system. Regulatory acceptance
of behavioral tests in neurotoxicological
assessments became evident with the develop-
ment of neurotoxicity testing guidelines by
the U.S. Environmental Protection Agency
(U.S. EPA) (7), many of which include
behavioral end points.
A second development was the evolution
oftiered testing strategies in which each stage
ofevaluation incorporates decision points as
to whether available information is sufficient
for determining the neurotoxicity ofa chem-
ical (8). For example, Evans and Weiss (9)
outlined a three-tier testing scheme, includ-
ing hazard identification, characterization,
and assessment of human susceptibility.
First-tier tests include neurological screening
batteries, cage-side observations, and
measures such as motor activity and grip
strength. Neuropathological observations
may also be used in the first tier in conjunc-
tion with the functional tests. If a chemical
was observed to be neurotoxic in the first
tier, a decision to characterize the chemical,
i.e., move to the second tier, would have to
be made. Characterization studies might be
based on results from the first tier, already
existing published data, or on new toxico-
logical data suggesting that the chemical
may pose a human neurotoxic risk. Second-
tier tests are designed to focus on specific
aspects of chemical-induced neurotoxicity.
For example, a second-tier test might be
used to determine effects of a chemical on
cognitive function such as attention or sen-
sory function such as visual acuity. Evans
and Weiss (9) also suggested a third tier to
assess human susceptibility to chemicals,
using methods analogous to those employed
in animal studies. In 1992, the National
Research Council (NRC) (10) published a
book on environmental neurotoxicology
describing a three tier-testing scheme similar
to that ofEvans and Laties (6) but included
mechanistic rather than human studies in the
third tier. A three-tier testing strategy was
recently endorsed by the European Chemical
Industry Ecology and Toxicology Centre
(11). The relative limitations ofa tier-testing
strategy within a regulatory context, however,
have been noted byTilson et al. (8).
A third development in the late 1970s
and 1980s that addresses Reiter's (1) concern
for a research strategy was the standardization
and validation ofmethods. In 1978, Tilson
and Cabe (12) noted the general lack oftest
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validation in animal models and suggested a
strategy aimed at resolving this problem.
These investigators proposed that test valida-
tion ofanimal models be accomplished by
evaluating known neurotoxicants in a battery
oftests chosen to assess effects reported in
humans. Bycomparing the observed results of
the neurotoxicants in the animal models with
the predicted effects, investigators could make
decisions concerning the validity ofselected
tests. This approach was used to validate the
National Toxicology Program behavioral
screening battery (13,14). Interlaboratory
studies to standardize and validate tests for
developmental neurotoxicology were reported
by Kimmel et al. (15), whereas an interna-
tional collaboration on neurobehavioral
screening methods was completed only
recently (16). A number ofstandardized test
batteries now exist for initial assessment of
chemicals forpotential neurotoxicity (17).
In summary, the 1980s brought a greater
acceptance ofbehavioral techniques in neuro-
toxicological studies. In addition, a large
increase occurred in the number ofstudies
reporting the effects ofchemicals on the ner-
vous system. Although these studies added
gready to our knowledge about which chemi-
cals affect nervous system integrity, many
were not mechanistically driven. Many test
methods were also developed, standardized,
and validated, which helped lead to develop-
ment ofneurotoxicity testing guidelines and
routine use ofneurotoxicological end points
in hazard identification.
Neurotoxicology in the 1990s
In 1990, Tilson (2) identified several research
gaps in neurotoxicological research. For
example, research was needed to develop, val-
idate, and interpret biological markers of
exposure and effect for use in humans.
Biomarkers are early indicators ofvariation in
cellular or biochemical components or
processes-structures offunctions that are
measurable in a biological system or sample.
Many papers were published in the 1990s
describing the effects ofchemicals on struc-
tural and functional end points, and many of
these meet the definition ofa biomarker of
effect. For example, chemically induced
injury to the central nervous system may be
accompanied by hypertrophy ofastrocytes,
and in some cases, these astrocytic changes
can be seen at the light microscopic level with
immunohistochemical stains for glial fibril-
lary acidic protein (GFAP), the major inter-
mediate filament protein in astrocytes. GFAP
has been proposed as a marker ofastrocyte
reactivity or as a response ofthe nervous sys-
tem to injury. The interpretation ofchemical-
induced increases in GFAP as a biomaker of
neurotoxic effect can be augmented by cor-
roborative results from neuropathology, and
measures ofGFAP are now included in the
neurotoxicity screening battery of the
U.S. EPA (7).
An example of a commonly accepted
biomaker of exposure is plasma acetyl-
cholinesterase (AChE) activity. Organo-
phosphate and carbamate pesticides inhibit
the activity ofAChE, which is an enzyme
that hydrolyzes the neurotransmitter acetyl-
choline (ACh). Inhibition ofAChE prolongs
the action ofACh in the synaptic cleft and is
associated with a range ofcholinomimetic
effects produced by these compounds.
Decreases in plasma AChE are now generally
accepted as a biomarker of exposure to
organophosphate and carbamate pesticides.
However, such changes are not always associ-
ated with the presence of clinical signs of
cholinergic overstimulation, so they are not
regarded as a biomarker ofneurotoxic effect.
Identification ofother biomarkers ofneuro-
toxic effect and exposure for hazard identifi-
cation and risk assessment remains a high
priority for future research. Such biomarkers
may also be useful in the development of
biologically based dose-response models.
Tilson (2) also noted that in vitro models
for neurotoxicity assessment should be used
with greater frequency in the 1990s. This
prediction was based on the need to screen
large volumes ofagents for potential neuro-
toxicity in a cost-effective and timely manner
and the relative success ofin vitro techniques
in other areas oftoxicology hazard identifica-
tion. The possibility of using in vitro tech-
niques for the routine screening of
neurotoxicity was recently addressed by an
IPCS work group (18). They pointed out
that in vitro procedures generally do not take
into account distribution ofthe toxicant in
the body, route ofadministration, or metab-
olism ofthe substance. Furthermore, they
noted the difficulty in extrapolating in vitro
data to many animal or human neurotoxicity
end points, including behavioral changes,
motor disorders, sensory and perceptual dys-
function, and cognitive deficits. The group
emphasized, however, that in vitro systems
are well suited to study biological processes
in more isolated conditions and have been
used successfully to understand mechanisms
oftoxicity, identify target sites ofaction, and
characterize the cellular and molecular
changes induced by exposure to neurotoxi-
cants. Harry et al. (18) conclude that in vitro
tests have their greatest potential in provid-
ing information on basic mechanistic
processes to refinespecific experimental ques-
tions to be addressed in the whole animal.
Therefore, a battery of in vitro tests selected
for the ability to detect specific mechanisms
ofneurotoxicity or sites ofeffect might even-
tually be developed for neurotoxicology
hazard identification.
Tilson (2) also notes that research is
needed to clarify the role that environmental
factors appear to play a role in the etiology of
some neurodegenerative diseases. For exam-
ple, several neurodegenerative diseases such
as amyotrophic lateral sclerosis-Parkin-
sonism-dementia complex, neurolathyrisms,
and mussel poisoning have been associated
with excitatory amino acid-induced neuronal
damage (19), whereas exposure to 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine has
been shown to produce a Parkinson's-like
syndrome in humans and experimental ani-
mals (20,21). More recent research has
implicated young-onset Parkinson's disease
(22) and extrapyramidal disorders (23) to
exposure to pesticide agents. Clearly, this is
an important area for future research, since
some neurodegenerative diseases appear to
have a genetic component that could be
affected by environmental influences.
It is now widely recognized that human
environmental exposure to chemicals is not
associated with a single chemical (24).
Because exposure may occur eithersimultane-
ously or sequentially to large numbers of
agents from different sources or by differing
routes, there are few commonly accepted
approaches for the risk assessment of mix-
tures. Tilson (2) noted the need to determine
if the neurotoxicity ofindividual chemicals
differs quantitatively and qualitatively from
that of the same chemicals in a mixture.
Some experiments with mixtures of neuro-
toxic agents suggest that they act in an addi-
tive or less-than-additive fashion. For
example, Rebert et al. (25) exposed rats by
inhalation to pairs ofsolvents that cause hear-
ing damage when given individually. Hearing
loss was evaluated using electrophysiological
techniques and the effectswere predicted by a
linear dose-additive model, indicating an
additive rather than a synergistic or antago-
nistic interaction. Kodavanti and Ward (26)
studied the interactive effects ofseveral poly-
chlorinated biphenyl (PCB) congeners in
vitro. Their results also suggest that the bio-
logical effects ofmixtures ofPCB congeners
fit a dose-additive model. It is clear that
understanding the toxicology ofchemicals in
mixtures is a complex problem, and better
mechanistic information will be needed to
predict synergistic effects.
Tilson (2) also pointed out that neurotox-
icology risk assessment would grow during
the 1990s. During this decade, significant
progress has been made to develop and vali-
date methods to screen and characterize all
classes ofneurotoxicants, to better understand
structure-activity relationships for several
dasses ofchemicals, to improve extrapolation
from animal data to human risk, and to char-
acterize neurotoxic mechanisms for some
chemicals. This progress s indicated by the
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publication ofthe U.S. EPA neurotoxicology
risk assessment guidelines (27), which
describe the principles, concepts, and proce-
dures that the agency uses in evaluating data
on potential neurotoxicity associated with
exposure to environmental toxicants.
However, significant issues for neurotoxicol-
ogy risk assessment remain, including the use
ofmechanistic data in risk assessment calcula-
tions, development ofmore quantitative risk
assessment models, and determination ofade-
quate protection for susceptible subpopula-
tions such as infants, children, and the elderly.
In summary, significant progress was
made during the 1990s in many of the
research areas identified byTilson (2), includ-
ing biomarkers, use ofin vitro techniques in
neurotoxicology, chemical mixtures, environ-
mentally associated neurodegenerative disor-
ders, and neurotoxicology risk assessment.
However, significant research gaps remain,
particularly in our understanding of neuro-
toxic mechanisms, the etiology of neurode-
generative diseases, and the behavior of
chemicals in mixtures.
Neurotoxicology in the
New Millennium
The discipline ofneurotoxicology continues
to grow and evolve. Research to elucidate
mechanisms ofneurotoxicity and neurode-
generative disease is needed to identify poten-
tial environmental causes ofenvironmental
disease and to develop possible treatments. In
the area ofhazard identification, research is
needed to develop and validate short-term in
vitro tests or batteries oftests that can detect
potential neurotoxicants on the basis of
mechanism ofaction. Indeed, mechanistic
data are needed to construct and validate bio-
logically based dose-response models that can
be used in neurotoxicology riskassessment.
Future research will continue to focus on
mechanisms underlying differential respon-
siveness to chemical exposure by various sub-
populations. For example, research is needed
to provide comparative pharmacokinetic data
forpossible sensitive populations and to iden-
tify genetic contributions underlying differen-
tial responsiveness to chemical exposure.
Much future research will continue to focus
on the problems ofchildren and infants. For
example, there is a need to elucidate the func-
tional modalities that may be altered follow-
ing developmental exposure and to develop
improved animal models to examine the neu-
rotoxic effects ofexposure during the premat-
ing and early postmating periods and in
neonates. Researchers need to better under-
stand the relationship between maternal and
developmental neurotoxicity and to provide
information concerning the concept of a
threshold for certain types ofdevelopmental
neurotoxicological effects.
The toxicological assessment ofchemical
mixtures remains a very complex problem.
Research is needed to address mechanisms of
synergistic or antagonistic response ofchemi-
cals given together via the same or differing
exposure media. Additional research is
needed to improve animal models for exam-
ining the effects ofagents given by various
routes ofexposure and determine the effects
ofrecurrent exposures over prolonged periods
oftime. Such research will aid in the evalua-
tion and interpretation ofdata obtained from
real-world environmental exposures and will
lead to methods to assess risk more precisely.
Finally, research is needed to advance the
application ofmore quantitative models in
neurotoxicology risk assessment. Approaches
for improved mathematical modeling of
neurotoxic effects need to be developed ifneu-
rotoxicological data are to be used routinely in
risk assessment.
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